Record Q2 fiscal 2026 results at Central Garden & Pet (NASDAQ: CENT, CENTA) came in with net sales of $906 million, up 9% year over year, and diluted EPS of $1.28, up from $0.98 — a 31% jump. Gross margin expanded 30 basis points to 33.1%. The print stands in clear contrast to the cooling on the therapeutics side of pet, and it's the cleanest evidence yet that mass-channel pet aisle demand is intact.
Central Garden & Pet Q2 sales up 9%, EPS up 31%
Q2 fiscal 2026 net sales at Central Garden & Pet were $906 million, up 9% year over year. Diluted EPS came in at $1.28, beating consensus by approximately $0.21. Net income was $79 million versus $64 million a year earlier. Operating income rose to $114 million from $93 million.
Gross margin expanded 30 basis points to 33.1%, against a quarter where headline inflation has normalized.
Management maintained its full-year fiscal 2026 outlook for non-GAAP diluted EPS of $2.70 or better, citing margin discipline, growth investment, and portfolio optimization.
The company flagged that its newly formed distribution joint venture with Phillips Pet Food & Supplies — in which Central retains a 20% stake — is expected to reduce reported revenue by a low-teens percentage in the back half, with $0.03 to $0.05 per share of dilution from initial integration friction and non-cash purchase accounting.
The brand portfolio includes Aqueon, Kaytee, Nylabone, Pennington, and Avoderm, which sit between premium specialty and private label across grocery, mass, and pet specialty.
Why pet aisle demand is decoupling from therapeutics
The same week Zoetis reported US companion animal sales down 11% on softer end-market demand and competitive pressure, the mass-channel pet aisle posted its best quarter on record. Two stories. One pet parent.
1. Pet consumables are decoupled from pet healthcare. Demand softness on the Rx side isn't a household-budget story. It's a manufacturer-share and category-mix story. The pet parent is still buying. They're just buying differently — toys, treats, aquatics, small-animal, wild-bird, dog chews — and they're not pulling back on the things that come up at every aisle reset.
2. Margin discipline is the operator playbook of the moment. A 30-basis-point gross margin lift in a non-inflationary quarter says CENT is harvesting price, mix, and cost-out at the same time. For competitors in the same aisle (Spectrum Brands' Global Pet Care, plus the long tail of mid-market pet brands), the lesson is that the path to profit growth this year is operational, not topline-led. Bootstrappers should benchmark against CENT's 33.1% as the floor for "running the business well."
3. Portfolio optimization continues. The reference to portfolio work plus a JV-related 2H revenue headwind signals continued pruning. CENT has a track record of acquiring brands and either rationalizing SKUs or divesting underperformers. For brand founders considering a strategic exit to CENT or a similar mass-channel platform, the buy-side bar looks higher than it did 18 months ago.
4. The pet category isn't slowing. It's rotating. The right frame for Q1 and Q2 2026 is rotation, not slowdown: away from premium therapeutics, toward consumables; away from one-time purchases, toward routine repeat; away from specialty, toward mass and rural channels. CENT, Spectrum Brands' pet care segment, and Freshpet at Tractor Supply are all telling versions of the same story.
5. The mass channel is the durability story. Zoetis is exposed to vet-channel demand. CENT is exposed to grocery, mass, and pet specialty. Q2 says the mass shopper is showing up. That has implications for Petco's recovery thesis, for Walmart's premium pet expansion, and for any DTC pet brand evaluating its first wholesale lift.
What the JV revenue headwind means for 2H
JV impact magnitude: A low-teens percent headwind in reported revenue is material. Watch how much of the EPS guide preservation is structural margin versus one-time benefit.
EPS guide language: Whether CENT raises its EPS guide off the "or better" wording. That's the trigger for a multiple expansion.
Pet versus garden segment mix: Q2 fiscal calendar (ending late March) typically captures spring garden lift. The pet aisle read is most relevant from segment-level commentary, not the headline.
M&A appetite: Central has been an active acquirer through cycles. Watch for tuck-in announcements in functional treats, supplements, or small-animal categories where the buy-side bar has tightened.
Category mix in 2H: Whether pet aisle volume continues running ahead of garden as the seasonal mix flips. That's the read on whether the consumables-decoupling thesis holds beyond Q2.
Source: Central Garden & Pet Q2 FY2026 release via Business Wire
Other News
More stories shaping the pet industry this week. From funding rounds and product launches to regulatory shifts and retail strategy, stay ahead of what's driving the market.
Zoom Room returns to franchising with 18.2% same-store sales growth
Zoom Room reported 12.0% and 18.2% same-store sales growth in Q2 and Q3 after pausing development in late 2025, and 15.1% for units open more than a year. It now resumes franchise sales with two quarters of operating data, and a 550-gym target that implies about 120 openings a year.
MPM Products recertifies as a B Corp under B Lab's audited new standards
The owner of Applaws, Reveal and Encore is one of 20 UK companies in the first cohort to certify under B Lab's rewritten standards, which add third-party assurance and a five-year cycle. With the EU's sustainability label rules applying from September 27th, 2026, B Lab says an assured B Corp badge now qualifies as a valid label.
Cat food owner hands North America to its marketing chief
MPM Products, the owner of Applaws, Reveal and Encore, has named global CMO Samantha Greenwood president of North America. The US brings in more than 40% of company revenue, and we read the pick as fitting Partners Group's cat-focused growth thesis in a pet food category APPA expects to grow about 2% in 2026.